22 The safety of medicines is an essential part of patient safety. Global drug safety 23 depends on strong national systems that monitor the development and quality of 24 medicines. Poor quality medicines do not meet official standards for strength, quality, 25 purity, packaging and labelling. Hence, this study determines in-vitro quality 26 attributes of glibenclamide 5mg tablet marketed in Addis Ababa according to 27 drug monograph specifications. All tested brands meet the requirements for physical 28 inspection & complied specification for friability and hardness. Besides, the tested 29 brands met USP 38 specification for assay (99.96% to 108.85%) and for content 30 uniformity (AV values ranges from 3.35 to 10.04). In-vitro release tests were carried 31 out in phosphate buffer of 7.5 and 8.5 pH and showed drug release of ≥ 75%, met 32 USP 38 requirements. However, significant difference with respect to dissolution 33 profile among tested brands GL4 and GL6 were confirmed with comparator product 34 through model independent approach. Moreover, DE values were studied and 35 confirmed that GL4 and GL6 were not therapeutically interchangeable with innovator 36 product. 37 3 38 Introduction 39 Glibenclamide, which is also Glyburide in USA, is a second-generation sulfonylurea 40 oral hypoglycemic agent used in the treatment of noninsulin-dependent diabetes. It is 41 a Biopharmaceutical classification system (BCS) class II drug that has high 42 permeability and poor water solubility (Figure 1).[1] It is one of the most prescribed 43 long-acting anti-hyperglycemic agents that lower the blood glucose acutely by 44 stimulating the release of insulin from the pancreas, an effect dependent upon 45 functioning beta cells in the pancreatic islets. [2] 46 47 Figure 1. Chemical structure of Glibenclamide 48 49
Assay and content uniformity
150-cm column that contains packing L7 having flow rate of 2 ml per minute with 10 150 µl injection volume was used to carry out the assay measurement. [14] 151 152
The analysis result was computed with the following formula:
153
(1) = ( ) ( ) 100 C s is concentration of the reference standard; C u is concentration of unknown sample 156 Dissolution were withdrawn at pre-determined time points (5, 15, 30, 45 and 60 at 7.5 pH; 5, 15, 162 30 and 45 at 8.5 pH) and the withdrawn samples were replaced with respective buffer 163 solution. All samples were then filtered before being measured. HPLC system 164 equipped with a 254-nm detector and 4.6-mm x 25-cm column that contains packing 165 L7 for buffer medium of 7.5 pH and HPLC system equipped with a 215-nm detector 166 and 4.6-mm x 25-cm column that contains packing L7 for buffer medium of 8.5 pH 167 was used to carry out the dissolution measurement. The flow rate was adjusted at 2 ml 168 per minute and with 75 µl injection volumes for 7.5 pH buffer medium and 1.5 ml per 169 minute and with 50 µl injection volumes for 8.5 pH buffer medium. The systems were 170 functioned with relative standard deviation of NMT 2.0% for replicate injection.
[14]
171
The amount of dissolved glibenclamide was determined using the regression equation
172
computed with reference sample with the same buffer type.
174
The analysis result was computed using the following formula:
175
(2) % = ( ) ( ) . 100
176
Where; A u is peak response of the sample, A s is peak response of the reference 177 C s is concentration of the reference, L c is label claim, V is dissolution volume 178 And, using regression equation:
Where; m is the slope, b is the intercept
The dissolution pattern of the drug was analyzed using both model-dependent were weighed again and the difference in weight will be calculated as the percentage.
199
A maximum weight loss of not more than 1% of the weight of the tablets being tested 200 are not allowed.
202
The result of the test was computed using the following formula:
Where W 1 is initial weight of randomly chosen 20 tablets, W 2 is after subjecting the 205 tablets to the friabilator for 4 minutes at 25 revolutions per minute, the final weight.
206

Uniformity of weight 207
Twenty tablets from each of the brand was weighed individually using analytical 208 balance. The average weights of the tablets for individual brand and their deviation 209 from the average weight was calculated.
210
And % of weight variation was calculated using the following formula:
100%
212
Where W x is individual weight, W av. is average weight tested tablets,
System verification 218
Method accuracy/recovery 219 As indicated in International Conference on Harmonization (ICH) guideline Q2B, 220 system recovery was done by adding known amount of standard in the blank. The
221
working standard has been prepared in three different concentrations (one from the 222 lower, one from the middle and one from the higher amount) with in the range of 70% 
Method Precision
233
The repeatability of the method was checked by using prepared working standards at 234 three different concentrations of 90%, 100%, and 110% within the range of 80% to 235 120% as clearly stated in the ICH Q2B guideline. So, triplicate injections from each 236 concentration were injected to the system and the RSD for individual concentration 237 was computed. The calculated Relative Standard Deviation (RSD) values for 90%,
238
100% and 110% were 0.07, 0.05 and 0.20 respectively. Thus, the method is proved to 239 be fit for the purpose since the RSD values are below acceptable maximum limit of 2 Table 2 . 
Method linearity 250
The linearity of the method has been verified by using five different concentrations 251 within the range of 80% to 120%. Triplicate injection from each concentration has 252 been injected to the system and RSD for individual concentration were computed. The
253
system was found to be fit for the purpose as the calculated RSDs for all 254 concentration become less than 2% which is the maximum acceptable limit stated in 
260
For a dissolution test, methods linearity was computed by using regression equation: Table 3 with their full description.
279
280 [14] As presented in Table 5 , the assay results of tested glibenclamide 311 brands were found to be within the range of 99.97% to 108.85% which was within 312 USP 38 assay specification (90% to 110%). However, brands GL1 and GL6 failed to 313 pass British Pharmacopeia (BP) and European Pharmacopeia (Ph.Eur) specifications 314 for assay (95% to 105%). There were reports of similar incidents that showed some of 315 the generics were not in line with BP, Ph.Eur. and International Pharmacopeia (Ph.
316
Int.) specification for their API contents.
[7] Among all tested glibenclamide products,
317
GL1 had higher assay value of 108.85% whereas GL5 had lower assay value of 318 99.97%.
319 320 
345
In this study, dissolution tests were conducted with paddle dissolution apparatus as 346 specified in USP-38 monograph for glibenclamide tablet preparation using phosphate 347 buffer as a dissolution medium at 7.5 and 8.5 pH values.
348
349
The dissolution profiles of tested products at 7.5 pH phosphate buffer, as indicated in 
356
The two way ANOVA analysis of the dissolution data at 45 min for all tested brands 357 showed that the dissolution behavior between different brands of glibenclamide tablet were not equivalent statistically with the comparator product with respect to their drug 361 release profile at 95% CI. GL1, GL2, GL3 and GL6 were found to be significantly 362 different in their drug release phenomena from comparator (GL5) product at 45 min (t 363 stat > t crit).
365
The dissolution profiles of the generic and the innovator products at 8.5 pH phosphate 366 buffer were presented in Fig 7. Since all tested brands exhibits drug release behavior 367 of more than 75% at 30 minutes, it can be concluded that all tested glibenclamide 368 tablets met USP-38 monograph requirements. The two way ANOVA analysis performed at 95% CI for the pharamacopoeially 373 specified time, 30 minutes, found that there were significant differences in the release 374 pattern of different glibenclamide brands (F > F crit; P < 0.05). As a result, post
375
ANOVA t-tests with Bonferroni correction was done to observe the source of 376 dissimilarity between comparator (GL5) and the tested generics at 95% CI. This 377 comparative analysis showed that GL4 and GL6 were significantly different in their 378 drug release pattern at 30 min when compared with the comparator product.
379
Dissolution profile evaluation 380
Model-independent approach of difference factor (f 1 ) and similarity factor (f 2 ) was 381 computed for in-vitro dissolution profile studies to demonstrate the equivalence of all 382 the generic glibenclamide tablets and the comparator product.
[19] To ensure 383 similarity and bioequivalence of two dissolution profiles, f 1 should be between 0 and GL3 were found to be similar in their dissolution behavior with comparator product 386 (GL5) whereas GL6 was not. The similarity and dissimilarity values of tested 387 products at pH of 7.5 and 8.5 were presented in 
415
Moreover, the generics can be interchangeable for brand/innovator products when the 416 difference between their dissolution efficiencies is within appropriate limits (±10%).
417
[15, 20] Hence, it can be concluded that GL1, GL2 and GL3 had similar drug release 418 profile with comparator (GL5) unlike GL4 and GL6 since their DE difference falls 419 within the range of ±10%.
420
Conclusions 421
This study evaluated the physicochemical quality and dissolution profile of six 422 commercially available glibenclamide brands. The physical characteristic tests 423 conducted on all tested product showed no deviation from the required specifications 424 for hardness, friability, weight variation, package integrity and labeling completeness. brands GL4 and GL6 were confirmed with comparator product through model statistically significant differences in assay and dissolution profiles associated with 432 the tested drugs are likely to reflect potential differences in clinical performance.
433
Therefore, properly controlled bio-equivalence studies are strongly recommended to 434 further investigate the potential problem that might associate with generic products. 
